Lunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on AI-Powered Therapeutics and Biodefense
Rhea-AI Summary
Lunai Bioworks (NASDAQ:LNAI), formerly known as Renovaro Inc., has unveiled its new corporate identity alongside a 10:1 reverse stock split that reduces outstanding shares from 231.8 million to 23.2 million. The company's rebranding reflects its strategic focus on AI-powered drug discovery and biodefense.
Key developments include the launch of a proprietary transformer-based platform for neurotoxicity intelligence, advancement of a preclinical Parkinson's Disease biomarker program through subsidiary BioSymetrics, and securing a multi-year NIH STTR grant. The company's Augusta platform aims to advance precision neurology through AI-integrated therapeutics and biomarker intelligence.
Positive
- Successful implementation of 10:1 reverse stock split to meet Nasdaq minimum bid requirements
- Secured multi-year NIH STTR grant for platform expansion
- Launch of proprietary transformer-based platform for neurotoxicity intelligence
- Advancement in Parkinson's Disease biomarker discovery program
Negative
- Significant share reduction from 231.8M to 23.2M shares through reverse split may indicate previous trading price concerns
Insights
Lunai's rebranding and reverse split signal strategic refocus on AI drug discovery and biodefense, creating clearer investment thesis but diluting shareholder value.
Lunai Bioworks' transformation from Renovaro represents a strategic pivot to position itself at the intersection of AI, drug development, and biodefense - three potentially lucrative sectors with significant government and private funding. The 10:1 reverse split immediately reduces outstanding shares from
This financial engineering appears primarily designed to maintain Nasdaq listing compliance by lifting share price above minimum thresholds, suggesting previous price weakness. Reverse splits are typically viewed cautiously as they often follow periods of significant share price deterioration and effectively dilute shareholders' ownership percentage.
The company's scientific developments show meaningful progress: their transformer-based platform embeds neurotoxicity intelligence into AI pipelines - addressing a critical safety challenge in drug development where neurotoxicity frequently derails otherwise promising compounds. Their Parkinson's biomarker program leverages phenogrouping (categorizing patients by disease manifestation patterns rather than broad diagnosis), potentially enabling more targeted therapies. Securing competitive NIH funding through an STTR grant provides external validation of their scientific approach and offers non-dilutive capital.
The biodefense angle is particularly strategic as it opens access to government contracts and grants, offering potential revenue streams independent of the traditional lengthy drug development timeline. However, investors should note the company remains pre-revenue with emphasis on platform development rather than late-stage candidates nearing commercialization.
LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 30, 2025 / Lunai Bioworks Inc. (Nasdaq:LNAI), a pioneer in AI-powered drug discovery and biodefense, today announced the formal adoption of its new corporate identity, reflecting a sharpened strategic focus and a streamlined capital structure following a 10:1 reverse stock split.
The rebranding from Renovaro Inc. to Lunai Bioworks marks a pivotal evolution in the company's mission: to capture biological signals at scale, decode them using AI, and validate them quickly in model systems. The new identity underscores Lunai's dual commitment to therapeutic innovation and biodefense preparedness, positioning the company as a category leader at the intersection of artificial intelligence, healthcare, and global security.
Effective September 30, 2025, Lunai's common stock will trade under the new ticker symbol "LNAI" on the Nasdaq Capital Market. The reverse stock split reduces outstanding shares from approximately 231.8 million to 23.2 million, enhancing capital efficiency and aligning with Nasdaq's minimum bid price requirements.
"Our new identity reflects both who we are and where we're going," said Dr. Gabe Musso, Chief Scientific Officer of Lunai's wholly owned subsidiary, BioSymetrics Inc. ("BioSymetrics"). "We're building platforms that not only accelerate therapeutic discovery but also safeguard against emerging biological threats."
Recent milestones include:
Transformer Platform Launch: Lunai introduced a proprietary transformer-based platform that embeds neurotoxicity intelligence into generative AI pipelines. This innovation enables safe compound discovery while mitigating dual-use risks in biodefense.
Parkinson's Biomarker Program: Through BioSymetrics, Lunai advanced a preclinical biomarker discovery initiative in Parkinson's Disease, leveraging phenogrouping and multimodal data to stratify patients and identify novel therapeutic targets.
Platform validation via a competitive NIH grant: BioSymetrics recently was successful in obtaining a multi-year STTR grant which will allows for platform expansion.
Capital Structure Optimization: The reverse stock split strengthens Lunai's financial profile, supports long-term growth, and facilitates strategic partnerships with pharma, biotech, and government agencies.
David Weinstein, CEO of Lunai Bioworks, commented:
"With our Augusta platform, Lunai Bioworks is advancing precision neurology through AI-integrated therapeutics and biomarker intelligence. This transformation reflects our commitment to restoring cognitive health and resilience at scale."
Lunai Bioworks remains committed to ethical innovation, translational science, and scalable collaboration. With a refined identity and robust platform, the company is poised to lead the next wave of AI-driven breakthroughs in medicine and biodefense.
About Lunai Bioworks, Inc.:
Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company pioneering safe and responsible generative biology. With proprietary neurotoxicity datasets, advanced machine learning, and a focus on dual-use risk management, Lunai is redefining how artificial intelligence can accelerate therapeutic innovation while safeguarding society from emerging threats.
Forward-Looking Statements:
This press release contains "forward-looking statements" within the meaning of the Private Litigation Reform Act of 1995 regarding the plans and objectives of management for future operations and market trends and expectations. Forward-looking statements can be identified by the fact that they do not related strictly to historical or current facts. Forward-looking statements are based upon our current assumptions, expectations and beliefs concerning future developments and their potential effect on our business. In some cases, you can identify forward-looking statements by the following words: "may", "could", "would", "should", "expect", "intend", "plan", "anticipate", "believe", "approximately", "estimate", "predict", "project", "potential" or the negative of these terms or other comparable terminology, although the absence of these words does not necessarily mean that a statement is not forward-looking. A forward-looking statement is neither a prediction nor a guarantee of future events or circumstances, and those future events or circumstances may not occur. You should not place undue reliance on forward-looking statements, which speak only as of the date of this Press Release. Forward-looking statements involve known and unknown risks, uncertainties, and other factors, that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations and assumptions that involve numerous risks and uncertainties. Our plans and objectives are based, in part, on assumptions involving the continued expansion of our business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. Lunai Bioworks encourages you to review the risk factors that may affect its future performance in its filings with the Securities and Exchange Commission. We are including this cautionary note to make applicable and take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additional information respecting factors that could materially affect the Company and its operations are contained in the Company's filings with the SEC which can be found on the SEC's website at www.sec.gov.
Investor Contact
David Weinstein
Chief Executive Officer
305-918-1980
http://www.lunaibioworks.com/
SOURCE: Lunai Bioworks Inc.
View the original press release on ACCESS Newswire
FAQ
What is the new stock symbol for Lunai Bioworks after rebranding from Renovaro?
What is the ratio and impact of Lunai Bioworks' reverse stock split in 2025?
What are the main focus areas of Lunai Bioworks' business strategy?
What recent technological developments has Lunai Bioworks announced?
What progress has Lunai Bioworks made in Parkinson's Disease research?
